TAGRISSO™ (OSIMERTINIB) POSITIVE CHMP OPINION

TAGRISSO™ (osimertinib) RECEIVES positive chmp OPINION FOR patients with EGFR
T790M mutation-positive METASTATIC non-small cell lung cancer

CHMP positive recommendation is based on an objective response rate of 66% and
median progression-free survival of 9.7 months

AstraZeneca today announced that the Committee for Medicinal Products for Human
Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion, recommending the marketing authorisation of TAGRISSO™ (AZD9291,
osimertinib) 80mg once-daily tablets for the treatment of adult patients with
locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M
mutation-positive non-small cell lung cancer (NSCLC).

This indication includes NSCLC patients whose disease has progressed on or after
treatment with an EGFR tyrosine kinase inhibitor (TKI) and patients with a T790M
mutation who have not been treated with an EGFR-TKI.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief
Medical Officer at AstraZeneca, said: "The CHMP's recommendation for osimertinib
to receive marketing approval is a positive step for patients in Europe. This
follows the recent US accelerated approval of osimertinib and its adoption in
the UK under the Early Access to Medicines Scheme to meet urgent unmet need.
Building on the breakthrough clinical evidence, we're investigating
osimertinib's full potential as a monotherapy and in novel combinations with
other precision medicines and immunotherapies from our comprehensive oncology
pipeline."

AURA study clinical investigator Professor Jean-Charles Soria, Head of Drug
Development Department, Gustave Roussy Cancer Center, Paris, France added; "In
Europe, lung cancer kills over 260,000 people every year, so there is an urgent
need for new treatments. As a treating physician, it is very gratifying to see
the progression of osimertinib towards use in clinical practice for patients
living with EGFRm T790M non-small cell lung cancer."

Osimertinib is an EGFR-TKI designed to inhibit both the activating, sensitising
mutation (EGFRm), and T790M, a genetic mutation responsible for EGFR-TKI
treatment resistance. Nearly two-thirds of patients with EGFRm NSCLC whose
disease progresses after EGFR-TKI treatment develop the T790M resistance
mutation, for which treatment options are limited.

The CHMP recommendation for osimertinib is based on data from two Phase II
studies (AURA extension and AURA2) and the AURA Phase I expansion study, which
demonstrated efficacy in 474 EGFRm T790M NSCLC patients who had progressed on or
after an EGFR-TKI. In the combined Phase II studies, the objective response rate
(ORR, a measurement of tumor shrinkage) was 66%, and in the Phase I study it was
62%. Progression-free survival (PFS) was 9.7 months in the combined Phase II
studies and 11 months in the Phase I trial. Median duration of response (DOR) in
the Phase I study was 9.7 months and in the combined Phase II studies, median
duration of response was not reached.

The most common adverse events based on data from the two AURA Phase II studies
were generally mild to moderate and included diarrhoea (42% all grades; 1.0%
Grade 3/4), rash (41% all grades; 0.5% Grade 3/4), dry skin (31% all grades; 0%
Grade 3/4), and nail toxicity (25% all grades; 0% Grade 3/4). Warnings and
precautions include interstitial lung disease, QT interval prolongation and
embryofoetal toxicity.

The positive CHMP recommendation has been received through the EMA's Accelerated
Assessment and follows the recent US Accelerated Approval of osimertinib by the
Food and Drug Administration (FDA). In Japan, osimertinib was granted Priority
Review by the Pharmaceuticals and Medical Devices Agency (PMDA). Interactions
with regulatory authorities in the rest of the world are ongoing.

About Non-Small Cell Lung Cancer (NSCLC)

Lung cancer is the leading cause of cancer death among both men and women,
accounting for about one-third of all cancer deaths, and more than breast,
prostate and colorectal cancers combined. Patients who have the EGFRm form of
NSCLC, which occurs in 10-15 percent of NSCLC patients in Europe and 30-40
percent of NSCLC patients in Asia, are particularly sensitive to treatment with
currently available EGFR-TKIs, which block the cell signalling pathways that
drive the growth of tumour cells. However, tumours almost always develop
resistance to treatment, leading to disease progression. In approximately two
-thirds of patients treated with the approved EGFR-TKIs, gefitinib, erlotinib or
afatinib, this resistance is caused by the secondary mutation, T790M.

About osimertinib

Osimertinib 80mg once-daily tablet is the first potential medicine indicated for
the treatment of adult patients with metastatic EGFR T790M mutation-positive
NSCLC. Non-clinical in vitro studies have demonstrated that osimertinib has high
potency and inhibitory activity against mutant EGFR phosphorylation across the
range of clinically relevant EGFRm and T790M mutant NSCLC cell lines, with
significantly less activity against EGFR in wild-type cell lines.

Osimertinib is being compared with platinum-based doublet chemotherapy in the
confirmatory AURA3 Phase III study in patients with EGFR T790M-positive, locally
advanced, or metastatic NSCLC who have progressed after EGFR-TKI therapy. It is
also being investigated in the adjuvant and metastatic first-line settings,
including in patients with brain metastases, and in combination with other
compounds.

About AstraZeneca in Oncology

Oncology is a therapeutic area in which AstraZeneca has deep-rooted heritage. It
will be potentially transformational for the company's future, becoming the
sixth growth platform. Our vision is to help patients by redefining the cancer
treatment paradigm and one day eliminate cancer as a cause of death. By 2020, we
are aiming to bring six new cancer medicines to patients.

Our broad pipeline of next-generation medicines is focused on four main disease
areas - lung, ovarian, breast, and haematological cancers. These are being
targeted through four key platforms - immuno-oncology, the genetic drivers of
cancer and resistance, DNA damage repair and antibody drug conjugates.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main therapy areas -
respiratory, inflammation, autoimmune disease (RIA), cardiovascular and
metabolic disease (CVMD) and oncology - as well as in infection and
neuroscience. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com

CONTACTS

Media Enquiries
Esra Erkal-Paler     UK/Global            +44 20 7604 8030
Neil Burrows         UK/Global            +44 20 7604 8032
Vanessa Rhodes       UK/Global            +44 20 7604 8037
Karen Birmingham     UK/Global            +44 20 7604 8120
Jacob Lund           Sweden               +46 8 553 260 20
Michele Meixell      US                   +1 302 885 2677
Investor Enquiries
UK
Thomas Kudsk Larsen  Oncology             +44 7818 524185
Eugenia Litz         RIA                  +44 7884 735627
Nick Stone           CVMD                 +44 7717 618834
Craig Marks          Finance              +44 7881 615764
Christer Gruvris     Consensus Forecasts  +44 7827 836825
US
Lindsey Trickett     Oncology, ING        +1 240 543 7970
Mitch Chan           Oncology             +1 240 477 3771
Dial / Toll-Free                           +1 866 381 7277

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and
Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal

18 December 2015

-ENDS-